Home > Dermatology > EADV 2019 > Late-Breaking News > IL-17A blocker effective in paediatric psoriasis patients

IL-17A blocker effective in paediatric psoriasis patients

Expert
Dr Kim Papp, Probity Medical Research, Canada
Conference
EADV 2019
Trial
Phase 3, IXORA-PEDS

In a phase 3 study, the interleukin (IL)-17 blocker ixekizumab showed a similar efficacy in paediatric patients with moderate-to-severe psoriasis as previously demonstrated in adult patients [1].

Although the first symptoms of psoriasis symptoms present during childhood in one-third of patients, there is still an unmet need for effective and safe therapies for children and adolescents with moderate-to-severe plaque psoriasis. This was the rationale for the IXORA-PEDS study, presented at the EADV Congress by Dr Kim Papp (Probity Medical Research, Canada).

The study evaluated the efficacy and safety of ixekizumab in 203 psoriasis patients between 6 to 18 years old. In a double-blind induction period participants received ixekizumab (n=115; 40 mg, 80 mg, or 160 mg depending on body weight), etanercept (n=30; 0.8 mg/kg), or placebo (n=58) for 12 weeks. At week 12, all participants switched to...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on